BioSyent Inc. (CVE:RX – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Thursday. The stock traded as high as C$17.41 and last traded at C$17.37, with a volume of 3,329 shares trading hands. The stock had previously closed at C$17.15.
BioSyent Stock Up 1.1%
The stock has a 50 day moving average price of C$16.45 and a 200 day moving average price of C$15.02. The company has a debt-to-equity ratio of 6.85, a quick ratio of 6.91 and a current ratio of 2.07. The company has a market capitalization of C$194.76 million, a P/E ratio of 20.30 and a beta of 1.05.
Insider Transactions at BioSyent
In related news, Director Seyed Ahmad Ashrafi sold 2,900 shares of the firm’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of C$16.55, for a total transaction of C$47,995.00. Following the completion of the sale, the director owned 21,461 shares in the company, valued at approximately C$355,179.55. This trade represents a 11.90% decrease in their ownership of the stock. Insiders have sold a total of 7,251 shares of company stock worth $118,207 in the last three months. Company insiders own 33.65% of the company’s stock.
About BioSyent
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
Further Reading
- Five stocks we like better than BioSyent
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.
